Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics

Int J Mol Sci. 2020 May 4;21(9):3248. doi: 10.3390/ijms21093248.

Abstract

The aim of this work is to analyze relevant endogenous lipid processing pathways, in the context of the impact that lipids have on drug absorption, their therapeutic use, and utilization in drug delivery. Lipids may serve as biomarkers of some diseases, but they can also provide endogenous therapeutic effects for certain pathological conditions. Current uses and possible clinical benefits of various lipids (fatty acids, steroids, triglycerides, and phospholipids) in cancer, infectious, inflammatory, and neurodegenerative diseases are presented. Lipids can also be conjugated to a drug molecule, accomplishing numerous potential benefits, one being the improved treatment effect, due to joined influence of the lipid carrier and the drug moiety. In addition, such conjugates have increased lipophilicity relative to the parent drug. This leads to improved drug pharmacokinetics and bioavailability, the ability to join endogenous lipid pathways and achieve drug targeting to the lymphatics, inflamed tissues in certain autoimmune diseases, or enable overcoming different barriers in the body. Altogether, novel mechanisms of the lipid role in diseases are constantly discovered, and new ways to exploit these mechanisms for the optimal drug design that would advance different drug delivery/therapy aspects are continuously emerging.

Keywords: fatty acid; glyceride; lipid; oral drug absorption; phospholipase A2 (PLA2); phospholipid; prodrug; steroid.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Carriers*
  • Drug Delivery Systems*
  • Drug Liberation
  • Humans
  • Lipid Metabolism*
  • Lipids* / chemistry
  • Metabolic Networks and Pathways*
  • Solubility
  • Structure-Activity Relationship

Substances

  • Drug Carriers
  • Lipids